Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $488M | $0.00 | $5.39M | $64.9M | $21.4M | $20.6M | $28.6M |
| Revenue growth | — | -100.0% | — | 1103.7% | -67.1% | -3.6% | 39.0% |
| Operating income | -$259M | -$402M | -$544M | -$590M | -$236M | $57.3M | -$396M |
| Operating margin | -53.1% | — | -10094.2% | -908.5% | -1103.4% | 278.3% | -1386.2% |
| Net income | -$261M | -$407M | -$573M | -$606M | -$271M | $25.4M | -$443M |
| Net margin | -53.5% | — | -10615.6% | -933.8% | -1267.9% | 123.6% | -1549.9% |
| EPS (diluted) | -$9.06 | -$14.16 | -$3.20 | -$2.85 | -$1.22 | $0.10 | -$1.69 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$165M | $223M | -$182M | $380M | -$272M | $978M | $1.09B |
| Capital expenditures | $26.0M | $14.0M | $25.9M | $29.0M | $25.6M | $27.9M | $36.4M |
| Free cash flow | -$191M | $209M | -$208M | $351M | -$298M | $950M | $1.06B |
| Share buybacks | $2.99M | $0.00 | $0.00 | — | — | — | — |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $337M | $826M | $1.10B | $1.56B | $1.87B | $1.53B | $2.77B |
| Total assets | — | $2.27B | $3.32B | $4.53B | $3.60B | $4.84B | $6.33B |
| Total liabilities | — | $1.82B | $1.93B | $3.63B | $2.80B | $3.82B | $5.34B |
| Long-term debt | — | $142M | $0.00 | $298M | $299M | $300M | $430M |
| Shareholders' equity | $0.00 | -$1.30B | $1.39B | $890M | $804M | $1.01B | $978M |
| Retained earnings | — | -$1.43B | -$2.00B | -$2.61B | -$2.88B | -$2.85B | -$3.29B |
| Shares (wtd avg diluted) | 28.8M | 29.3M | 179M | 212M | 222M | 266M | 262M |
Every figure is extracted from Oscar Health, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.